M
Madrigal Pharmaceuticals, Inc. (MDGL)
NMS – Real vaqt narxi. Valyuta: USD
510.26
+13.23 (2.66%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
510.26
+13.23 (2.66%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Madrigal Pharmaceuticals, Inc. – bu biofarmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda metabolik disfunksiyaga bog'liq steatohepatit (MASH) uchun yangi terapevtik vositalarni taqdim etishga qaratilgan. Kompaniya MASHni davolash uchun jigar uchun mo'ljallangan tiroid gormon retseptorlari beta agonisti bo'lgan Rezdiffra'ni taklif etadi. Kompaniya 2016-yilda tashkil etilgan va uning shtab-kvartirasi Pensilvaniya shtatining Vest Konshoxoken shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Soergel M.D. | Executive VP & Chief Medical Officer |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific & Medical Advisor and Director |
| Mr. Mark Underwood | Executive Vice President of Business Planning & Operations |
| Mr. Ronald Filippo | Executive VP & Chief Information Officer |
| Mr. William J. Sibold | CEO, President & Director |
| Ms. Carole Huntsman | Executive VP & Chief Commercial Officer |
| Ms. Mardi C. Dier | Executive VP & CFO |
| Ms. Rita Thakkar | Senior VP & Chief Accounting Officer |
| Ms. Shannon Kelley | Executive VP, Chief Legal Officer & Corporate Secretary |
| Ms. Tina E. Ventura | Chief Investor Relations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | mdgl-20260506.htm |
| 2026-05-06 | 10-Q | mdgl-20260331.htm |
| 2026-04-28 | DEFA14A | tm261619d3_defa14a.htm |
| 2026-02-19 | 10-K | mdgl-20251231.htm |
| 2026-01-30 | 8-K | tm264540d1_8k.htm |
| 2025-12-11 | 8-K | mdgl-20251205.htm |
| 2025-11-04 | 8-K | mdgl-20251104.htm |
| 2025-09-11 | S-8 | tm2525766d1_s8.htm |
| 2025-08-05 | 8-K | mdgl-20250805.htm |
| 2025-08-05 | 10-Q | mdgl-20250630.htm |